BioCryst prelims, 2024 outlook

 —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)—

—ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for
$1 billion in peak sales—

—Operating expenses expected to remain flat ($365-$375 million) in 2024—

—Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025—

https://www.globenewswire.com/news-release/2024/01/05/2804867/29446/en/BioCryst-Announces-Preliminary-Full-Year-2023-ORLADEYO-berotralstat-Net-Revenue-of-325-Million-Provides-2024-Guidance-and-Accelerated-Path-to-Profitability.html